Enrolled Patient Numbers
Randomized Clinical Trials (RCTs) have constituted the foundation for new drug approvals for over fifty years.
Randomized Clinical Trials (RCTs) have constituted the foundation for new drug approvals for over fifty years. An Institute of Medicines (IOM) report concluded though in 2008 that RCTs may become unsustainable because of the time and expense involved. In addition, as therapies become more targeted, the financial calculus may make these RCTs even more problematic.
Some industry critics have argued that the increasing number of patients in Phase III clinical trials is actually an industry strategy to improve the statistical strength of clinical trial results and RCTs will actually have to continue to increase in size. As differences between active and non-active arms become more difficult to establish, larger sample sizes are used to improve the chances of reporting statistically significant differences.1 Rather than a response to scientific necessity, the growing number of enrolled patients is a conscious strategy to improve the chances of a favorable regulatory approval decision.
ClinicalTrials.gov reports the actual number of targeted enrolled patients. ClinicalTrials.gov is a federally mandated database with a large, and growing, number of mandatory data fields. One of these mandated fields is number of patients. Another is therapeutic area. These data fields are particularly robust, with missing data under three percent. ClinicalTrials.gov requires that information be reported for any study operating under the auspices of the FDA. This analysis examines Phase III studies conducted by commercial pharmaceutical companies.
The average number of enrolled patients has not changed since 2008 when the enrolled patients variable became mandatory. Only one MedRHA therapeutic area--vascular disorders--shows a statistically significant difference from the overall results for the six years covered by the analysis. However, the number of patients has actually declined over the period in question.
1Adrian G. Sacher, Lisa W. Le, Natasha B. Leighl. Shifting patterns in the interpretation of phase III clinical trial outcomes in advanced non-small-cell lung cancer: the bar is dropping. Journal of Clinical Oncology. March 2014.
Average Patient Enrollment per Phase III Study by Year
Source: Department of Health Policy and Public Policy, University of the Sciences, Philadelphia, PA
Final ENLIVEN Trial Results Confirm Long-Term Benefit of Turalio in Tenosynovial Giant Cell Tumor
July 9th 2025In final data from the Phase III ENLIVEN study, Turalio (pexidartinib) demonstrated durable tumor responses and a consistent safety profile in patients with symptomatic TGCT not amenable to surgery.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
Effect of AI/ML, Real World Evidence and Master Protocols on Trial Success
July 7th 2025How the application of artificial intelligence, broader use of real-world evidence, decentralized clinical trials, master protocols, and risk-based quality monitoring, together with strong ethical oversight and increased collaboration, are contributing to better healthcare delivery and strengthening the role of clinical research in driving global health progress.
